Journals / Glokom Katarakt / 2010 / Cilt: 5 - Sayı: 3

Earlt outcomes of trabeculectomy with mit C after the ıntravitreal bevacizumab in neovascular glaucoma

Neovasküler glokomda intravitreal bevacizumab sonrası mitomisin-C'li trabekülektomide erken dönem sonuçlarımız

Pages
165–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this way, an extra time can be saved for additional interventions that would treat the specific underlying condition that results with NVG.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To assess the impact of intravitreal bevacizumab (IVB) on the following surgical complications and early results of trabeculectomy with mitomycin-C in neovascular glaucoma (NVG).
📊
Key Findings & Data:Materials and Methods: Cases with the diagnosis of NVG and intraocular pressures >40 mmHg, visual acuities between hand-motion and 0,1 and prominent corneal edema were included in this study.
💡
Conclusion & Impact:In this way, an extra time can be saved for additional interventions that would treat the specific underlying condition that results with NVG.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To assess the impact of intravitreal bevacizumab (IVB) on the following surgical complications and early results of trabeculectomy with mitomycin-C in neovascular glaucoma (NVG). Materials and Methods: Cases with the diagnosis of NVG and intraocular pressures >40 mmHg, visual acuities between hand-motion and 0,1 and prominent corneal edema were included in this study. Primarily, IOPs were assessed at the third day of intravitreal injections. Subsequently fornix based MMC trabs were performed 7 to 10 days after injections. Along with anterior segment photography, follow-up examinations were done on the first postoperative week and on the first month. Results: Ten eyes of 10 cases, between the age of 44 and 67 years (mean of 57.0±10), were included in this study. Five of the cases were male and the other five were female. Mean IOP reading was 35±4.5 mmHg (29-38 mmHg) on the third day of IVB injection. IOP were 12±3.2 mmHg (10-17 mmHg) and 15±3.2 mmHg (10-18 mmHg) respectively on the first postoperative week and on the first month. In all eyes, corneal edema regressed significantly and a diffuse filtering bleb was present. Discussion: In eyes with NVG, bevacizumab enables to perform an easier surgery and helps to maintain a better control of IOP postoperatively when it is injected intravitreally before MMC trab. In this way, an extra time can be saved for additional interventions that would treat the specific underlying condition that results with NVG.

Özet

Amaç: Neovasküler glokomlu (NVG) gözlerde mitomisin-C li trabekülektomi (MMC trab) öncesi yapılan intravitreal bevacizumabın (IVB) cerrahi komplikasyonlara ve erken dönem postoperatif sonuca etkisinin değerlendirilmesi. Gereç ve Yöntem: Çalışmaya kliniğimizde neovasküler glokom tanısı konan ve antiglokomatöz tedaviye rağmen göz içi basıncı >40 mmHg olan, Snellen eşelinde görmesi el hareketi ile 0.1 arasında olan ve belirgin kornea ödemi olan olgular dahil edildi. Olguların tümünde etyolojik faktör proliferatif diabetik retinopati idi ve tümüne tamamlanabildiği kadarıyla işlemler öncesinde panretinal fotokoagulasyonları yapıldı. İntravitreal enjeksiyonun steril şartlar altında yapılmasını takip eden 3. günde olguların GİB ları ölçüldü. Enjeksiyondan sonraki 7-10 gün içerisinde ise forniks tabanlı MMC trab uygulandı. Olguların peroperatuar komplikasyonları kaydedildi, MMC trab'dan 1 hafta ve 1 ay sonra rutin göz muayeneleri yapılıp ön segment fotoğrafları çekildi. Bulgular: Bu çalışmaya yaşları 44 ile 67 yıl arasında (ortalama 57.0±10) olan 10 hastanın 10 gözü dahil edildi. Olguların beşi erkek, beşi kadındı. İVB sonrası 3. günde ortalama GİB 35±4.5 mmHg (29-38 mmHg) olarak ölçüldü. Trabekülektomi sonrası 1. haftada ortalama GİB 12±3.2 mmHg iken (10-17 mmHg), 1. ayda ortalama GİB 15±3.2 mmHg (10-18 mmHg) idi. Takiplerde hiçbir olgu antiglokomatöz tedavi gerektirmedi. Yapılan son kontrollerinde olguların tümünde korneal ödemin gerilediği ve yaygın filtran blebleri olduğu görüldü. Filtran cerrahi esnasında veya erken dönemde komplikasyon ile karşılaşılmadı. Tartışma: NVG da MMC trab öncesi uygulanan IVB, trabekülektomiyi kolaylaştırmakta ve postoperatif GİB kontrolüne yardımcı olmaktadır. Böylece neovaskülarizasyona sebep olan ve NVG ile komplike olan durumun tedavisine yönelik ilave zaman kazanılmaktadır.

🔖

Cite This Article

BAYKARA, M., YALÇINBAYIR, Ö., ULUTAŞ, B. G., YILDIRIM, Y., ÖZÇETİN, H. (2010). Earlt outcomes of trabeculectomy with mit C after the ıntravitreal bevacizumab in neovascular glaucoma. Glokom Katarakt, Cilt: 5 - Sayı: 3, 165–168. https://ajindex.com/articles/226929

References (14)

  1. Johnson M, Gong H, Freddo TF, et al.: Serum proteins and aqueous outflow resistance in bovine eyes. Invest Ophthalmol Vis Sci. 1993;34:3549-3557
  2. Kubota T, Tawara A, Hata Y, et al.: Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. Br J Ophthalmol. 1996;80:750-754
  3. Tripathi RC, Li J, Tripathi BJ, et al.: Increased levels of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232-237
  4. Oshima Y, Sakaguchi H, Gomi F, et al.: Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-158
  5. Barkmeier AJ, Akduman L.: Bevacizumab (Avastin) in ocular processes other than choroidal neovascularization. Ocular Immunulogy& Inflammation. 2009;17:109-117
  6. Kahook MY, Olson JL.: Treating neovasculer glaucoma with intravitreal bevacizumab. Techniques in Ophthalmology. 2007; 5:150-153
  7. Sivak-Callcott JA, O’Day DM, Gass JD, et al.: Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1776
  8. Kelkar AS, Kelkar SB, Kelkar JA, et al.: The use of intravitreal bevacizumab in neovascular glaucoma: a case report. Bull Soc Belge Ophthalmol. 2007;303:43-45
  9. Jonas JB, Spandua UH, Schlichtenbrede F.: İntravitreal Bevacizumab for Filtering Surgery. Ophthalmic Research. 2007;39:121-122
  10. Saito Y, Higashide T, Takeda H, et al.: Benefical effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovasculer glaucoma. Acta Ophthalmologica. 2009
  11. Kitnarong N, Chindasub P, Metheetrairut A.: Surgical outcome of intravitreal bevacizumab and filtration surgery in neovasculer glaucoma. Adv. Ther. 2008;25:438-443
  12. Cornish KS, Ramamurthi S, Saidkasimova S, et al.: Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye. 2009:23;979-981
  13. Lüke J, Lüke M, Grisante S.: Antiangiogene therapie bei neovaskularem glaukom und nach filterkissenchirurgie. Ophthalmologe. 2009;106:407-412
  14. Gheith ME, Siam GA, de Barros DS, et al.: Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther. 2007;23:487-491.